ÀÇ·áÁø ã±â
¾Æ·¡ °Ë»öÀ» ÅëÇØ Á¤È®ÇÏ°í ºü¸£°Ô ÀÇ·áÁøÀ» °Ë»öÇÒ ¼ö ÀÖ½À´Ï´Ù.
Áø·á°ú ¾È³»
[¹®ÀÇÀüÈ] 1577-9966
Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù. Ŭ¸¯ ½Ã ÇØ´ç Áø·á°úÀÇ ÀÚ¼¼ÇÑ »çÇ×À» º¸½Ç ¼ö ÀÖ½À´Ï´Ù.
°£¼¾ÅÍ
-
[±¹¿Ü³í¹®]
Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy
Kim JH, Yu SK, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Pak YT, Lee CH, Byun KS
/ Clinical outcomes of chronic hepatitis B patients with persistently detectable serum hepatitis B virus DNA during lamivudine therapy
/ 22(8):1220-5
/ 200708
-
[±¹¿Ü³í¹®]
Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy
Lee KS, Byun KS, Chung YH, Paik SW, Han JY, Yoo K, Yoo HW, Yoo BC, Lee Hs
/ Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy
/ 50(4):296-302
/ 200707
-
[±¹¿Ü³í¹®]
Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B
Yoo BC, Kim JH, Chung YH, Lee KS, Paik SW, Ryu SH, Han BH, Han JY, Byun KS, Cho M, Lee HJ, Kim TH, Cho SH, Park JW, Um SH, Hwang SG, Kim YS, Lee YJ, Chin CY, Kim BI, Lee YS, Yang JM, Kim HC, Hwang JS
/ Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B
/ 45(5):1172-8
/ 200705
-
[±¹¿Ü³í¹®]
A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B
Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, Yoo HW, Lee JH, Yoo BC
/ A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B
/ 43(5):982-8
/ 200605